Abstract:For the assessment of different chemical components in pharmaceutical and biological samples, High Performance Liquid Chromatography (HPLC) can be defined as a commonly utilized analytical method in pharmaceutical samples. HPLC offers high sensitivity, specificity, and accuracy, making it a preferred method for the analysis of complex samples. In this technique, the sample is prepared by extracting, purifying, and concentrating the target analyte from the matrix. Mobile and stationary phases are after that used in chromatographic separation of the prepared sample. Several detectors, including fluorescence, UV-vis, and mass spectrometry, are used to identify and measure the eluted compounds. HPLC is capable of estimating a wide range of elements, including small molecules, peptides, and proteins, making it an essential tool in pharmaceutical research and development. The theoretical plates, peak tailing, and % assay have not been significantly impacted by the deliberate alterations made to the method. This implies that the existing technique is robust. The low values of LOQ and LOD show how sensitive the suggested approach is. The current research used a standard drug solution with six replicates to examine the system suitability parameters. It was discovered that the computed parameters fell under the acceptable criteria. The theoretical plate count, tailing factor, and HETP parameters are all within acceptable ranges. The results of this work are compared with those of earlier research. Upon analyzing the chart, it can be inferred that the proposed method presents certain benefits. The investigation employed a Kromasil C18 column. The obtained retention time is comparatively lower than that of all other methodologies. The maximum quantifiable threshold is 600 μg/mL, surpassing or equating all of the aforementioned techniques. The duration of the execution is also minimal. Therefore, the author draws the conclusion that the HPLC method proposed exhibits sensitivity and reproducibility in analysis of etodolac and thiocolchicoside in combined tablet dosage form, while also requiring a short analysis time.

Estimating Butylated Hydroxytoluene in the Presence of Polymers such as Polyethylene Glycol and Polyethylene Oxide in Mirabegron Extended-Release Tablets

Development and Validation of UV and RP-HPLC Methods for Simultaneous Estimation of Mirabegron and Solifenacin Succinate in Their Pharmaceutical Dosage Form

High-performance thin-layer chromatography-based methodology for simultaneous estimation of bisoprolol fumarate and telmisartan

Simultaneous Method Development and Validation of Berberine, Rubiadin and 3-O-acetyl-11-keto-β-boswellic acid By Reverse Phase High Performance Liquid Chromatography In Polyherbal Formulation

Development and validation of RP HPLC method for simultaneous determination of picroside I, picroside II, phyllanthin and boeravinone B in a polyherbal hepatoprotective tablet formulation

Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder

Simultaneous Estimation of Netarsudil and Latanoprost by Stability Indicating RP-HPLC-Pda in Pure Binary Blend and their Ophthalmic Solution

Spectrofluorimetric determination of butylated hydroxytoluene and butylated hydroxyanisole in their combined formulation: application to butylated hydroxyanisole residual analysis in milk and butter

RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR QUANTITATIVE ESTIMATION OF TEMOZOLOMIDE AND (S) - PERILLYL ALCOHOL IN NANOPARTICULATE DOSAGE FORM

Diaryl pyrrolone fluorescent probing strategy for Mirabegron determination through condensation with ninhydrin and phenylacetaldehyde: Application to dosage forms, human urine and plasma

Development and Validation for the Simultaneous Quantification of Nebivolol Hydrochloride and Hydrochlorothiazide by UV Spectroscopy, RP-HPLC and HPTLC in Tablets

HPTLC-Densitometric Analysis of Eperisone Hydrochloride and Paracetamol in Their Combined Tablet Dosage Form

Robust high‐performance thin‐layer chromatography (HPTLC) method for stability assessment and simultaneous quantification of epigallocatechin‐3‐gallate and rosmarinic acid in lipid‐based nanoparticles and biological matrices

Development and Validation of a Robust RP-HPLC Method for the Simultaneous Analysis of Exemestane and Thymoquinone and Its Application to Lipid-Based Nanoformulations

Accurate Estimation of Some Pharmaceutical Compounds Using HPLC Technology

Plackett-Burman and face-centered composite designs for development and optimization of chromatographic method for the simultaneous determination of glycopyrronium, indacaterol and mometasone in their fixed dose combination inhaler - Green profile assessment

RP-HPLC Estimation of Bumetanide and its Impurities in Oral Solid Dosage Form

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF TERBUTALINE SULPHATE, GUAIPHENESIN AND AMBROXOL HYDROCHLORIDE FROM AN ORAL LIQUID

Analysis of some pharmaceuticals in the presence of their synthetic impurities by applying hybrid micelle liquid chromatography

Analytical method development and validation for simultaneous estimation of Bempedoic acid and Ezetimibe in pure and its pharmaceutical dosage form by RP‐HPLC

A stability indicating RP-HPLC-UV assay method for the simultaneous determination of hydroquinone, tretinoin, hydrocortisone, butylated hydroxytoluene and parabens in pharmaceutical creams